"
Team:Freiburg Bioware
From 2010.igem.org
| Line 32: | Line 32: | ||
<!---Box on the upper left: Project Summary---> | <!---Box on the upper left: Project Summary---> | ||
| - | <div class=" | + | <div class="box_home"> |
<a href="https://2010.igem.org/Team:Freiburg_Bioware/Project"> | <a href="https://2010.igem.org/Team:Freiburg_Bioware/Project"> | ||
<u2>Project Summary</u2> | <u2>Project Summary</u2> | ||
| Line 50: | Line 50: | ||
<!---Box on the lower left: Biosafety---> | <!---Box on the lower left: Biosafety---> | ||
| - | <div class=" | + | <div class="box_home"> |
<a href="https://2010.igem.org/Team:Freiburg_Bioware/Human_Practice/Biosafety"> | <a href="https://2010.igem.org/Team:Freiburg_Bioware/Human_Practice/Biosafety"> | ||
<u2>Biosafety</u2> | <u2>Biosafety</u2> | ||
| Line 59: | Line 59: | ||
<!---Box on the lower right: Cuckoo Clock Competition---> | <!---Box on the lower right: Cuckoo Clock Competition---> | ||
| - | <div class=" | + | <div class="box_home"> |
<a href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Cuckoo Clock"> | <a href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Cuckoo Clock"> | ||
<u2>Cuckoo Clock Competition</u2> | <u2>Cuckoo Clock Competition</u2> | ||
Revision as of 19:03, 8 October 2010
In the last years the number of people affected by cancer increased significantly. About 25% cases of death are caused by malign tumors. Even though the industry is putting great efforts into developing effective strategies against cancer, innovative methods to fight tumors are needed. This year’s aim of Freiburg Bioware team 2010 is to create a universal virus construction kit which can be designed by submitted BioBricks. Our goal is to knockout the natural tropism of adeno-associated virus particles and to specifically target tumor cells by genetic engineering of the viral surface. The recombinant viruses will contain different genes coding for enzymes which convert harmless drugs into toxic molecules in targeted cell and kill the tumor cells. This approach will be a great advance in improving the growing field of personalized medicine.
